HFS
MYGN icon

Hantz Financial Services’s Myriad Genetics MYGN Stock Holding History

Hantz Financial Services’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Sell
529
-5,769
-92% -$26.2K ﹤0.01% 2280
2026
Q1 		$28K Buy
6,298
+1,937
+44% +$10.1K ﹤0.01% 1754
2025
Q4 		$27K Buy
4,361
+272
+7% +$1.97K ﹤0.01% 1667
2025
Q3 		$30K Buy
4,089
+3,745
+1,089% +$22.2K ﹤0.01% 1420
2025
Q2 		$2K Buy
344
+333
+3,027% +$1.97K ﹤0.01% 2006
2025
Q1 		$0 Buy
+11
New +$132 ﹤0.01% 1885

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hantz Financial Services's MYGN Position: Q2 2026 in Review

Hantz Financial Services reduced its Myriad Genetics (MYGN) stake by 92% in Q2 2026, selling an estimated $26.2K and leaving 529 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

Hantz Financial Services first reported a position in MYGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $30K in Q3 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Hantz Financial Services held 529 shares of Myriad Genetics worth $3K as of Q2 2026.
  • Hantz Financial Services sold 5,769 Myriad Genetics shares in Q2 2026, an estimated $26.2K.
  • Myriad Genetics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2280 holding.
  • Hantz Financial Services first reported a position in Myriad Genetics in Q1 2025 and has held it in 6 quarters since.
  • Hantz Financial Services's Myriad Genetics position peaked at $30K in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.